Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
Active, not recruiting · NCT06762080 · Registry updated 2026-09-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis | Neoplasms by Site, central nervous system cancer, neoplasm, neoplastic meningitis, nervous system disorder, tumor of meninges | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-02 | NCT06762080 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Guangzhou Medical University | 33 |
| Jinshan Hospital Fudan University | 6 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Chest Hospital, Capital Medical University | Beijing | China | 3 |
| Jinshan Hospital, Fudan University | Shanghai | China | 3 |
| The Affiliated Huizhou Hospital, Guangzhou Medical University | Huizhou | China | 6 |